Blog
RSS FeedPosted by Michael Wonder on 22 Mar 2019
Ontario may lift ban preventing major pharmacies from selling private-label generic drugs
21 March 2019 - Ontario Premier Doug Ford’s government is considering lifting a ban that prevents major pharmacy chains from ...
Posted by Michael Wonder on 12 Mar 2019
FDA approves a new generic valsartan
12 March 2019 - Today, the U.S. FDA approved a new generic of Diovan (valsartan). ...
Posted by Michael Wonder on 07 Mar 2019
Drug price fix seen in supply of generics, rebates, Senator says
7 March 2019 - Middlemen, not consumers, get company discounts, Collins says. ...
Posted by Michael Wonder on 28 Feb 2019
“Repurposing” off-patent drugs offers big hopes of new treatments
28 February 2019 - Towards the end of 2014 a 66-year-old British man named Alistair had a seizure. A scan ...
Posted by Michael Wonder on 25 Feb 2019
Drug prices aren't falling despite more generics, report finds
26 February 2019 - More generic drugs are being approved in the U.S., but those copycat treatments likely aren’t having a ...
Posted by Michael Wonder on 22 Feb 2019
Statement from FDA Commissioner and Director of FDA’s Center for Drug Evaluation and Research on the FDA’s continuing efforts to maintain its strong oversight of generic drug quality issues domestically and abroad
22 February 2019 - At the FDA, protecting patient and consumer health is our highest priority. Assessing and mitigating risks ...
Posted by Michael Wonder on 21 Feb 2019
Indivior launches generic version of its Suboxone opioid drug
20 February 2019 - British drugmaker Indivior said on Wednesday it had launched a copycat version of its blockbuster opioid ...
Posted by Michael Wonder on 15 Feb 2019
Statement from FDA Commissioner on new policy to improve access and foster price competition for drugs that face inadequate generic competition
15 February 2019 - In too many cases, branded drugs that are no longer protected by patents or other exclusivities ...
Posted by Michael Wonder on 13 Feb 2019
Mylan launches Wixela Inhub (fluticasone propionate and salmeterol inhalation powder, USP), the first generic of Advair Diskus (fluticasone propionate and salmeterol inhalation powder), at a list price 70% less than the brand
12 February 2019 - Unique pricing of Wixela Inhub immediately benefits patients and reduces overall cost to the U.S. health care ...
Posted by Michael Wonder on 08 Feb 2019
Generic drug approvals surge, but hundreds still aren't for sale
7 February 2019 - The Trump administration has been trumpeting a huge increase in FDA generic drug approvals the past ...
Posted by Michael Wonder on 30 Jan 2019
Statement from FDA Commissioner on 2019 efforts to advance the development of complex generics to improve patient access to medicines
30 January 2019 - As part of the FDA’s efforts to promote drug competition and patient access, we’ve advanced many ...
Posted by Michael Wonder on 30 Jan 2019
FDA approves first generic Advair Diskus
30 January 2019 - The U.S. FDA today approved the first generic of Advair Diskus (fluticasone propionate and salmeterol inhalation ...
Posted by Michael Wonder on 30 Jan 2019
Statement from FDA Commissioner on the agency’s efforts to enhance the utility of the Orange Book to foster drug competition
30 January 2019 - One of our key policy priorities is encouraging the timely development and approval of generics and ...
Posted by Michael Wonder on 22 Jan 2019
Secretive 'rebate trap' keeps generic drugs for diabetes and other ills out of reach
19 January 2019 - Lisa Crook was lucky. She saved $800 last year after her insurance company started covering a ...
Posted by Michael Wonder on 16 Jan 2019
FDA approves first generic version of Sabril to help treat seizures in adults and paediatric patients with epilepsy
16 January 2019 - The U.S. FDA approved the first generic version of Sabril (vigabatrin) 500 mg tablets for treating complex ...